Path Fertility

Path SpermQT: A Fertility Test for Men and Couples

health AI / medtech / reproductive health

Visit website

YC batchFuel Accelerator

Raised$8.2 million

Founded2021

Employees4

LocationSalt Lake City, UT

Business modelB2B2C / SaaS (laboratory test service with clinical usage in practices)

About

Path Fertility works with doctors and fertility specialists to provide couples who are trying to conceive with answers. Using breakthrough technology, Path Fertility has developed a sperm analysis test that is more predictive of pregnancy than the current standard of care semen analysis alone. SpermQT examines epigenetic biomarkers and DNA methylation within the sperm head--looking beyond typical criteria of male fertility such as sperm count, motility, and concentration. Despite common misconceptions, fertility problems are common (1 in 6 people) and impact both men and women equally. The gender divide in both fertility testing and treatment has left not only a gap in potential interventions, but also in the emotional burden that partners experience. Path Fertility is on a mission to raise the standard of care for male reproductive health. Male fertility is a women's health issue. When subfertile men go undiagnosed, women are put through fertility treatments that will not work. Powered by Inherent Biosciences.

Product

Value proposition: SpermQT predicts pregnancy outcomes by measuring sperm function (not just count) to inform decisions like continuing with IUI or moving to IVF; it is quick, easy-to-use, non-invasive, and can be used in-office or at-home with a lab analysis.
Target customers: fertility clinics, reproductive health providers, clinicians, couples seeking fertility assessment

Founders

Andy Olson — Co-Founder & CEO
Kristin Brogaard — Co-Founder & CSO

Products

SpermQT

Key features

measures sperm function beyond countpredicts pregnancy outcomesnon-invasivein-office or at-home sample collectionlab analysis with results in ~2 weeks

Technologies

sperm function analysisclinical testinglaboratory analysispotentially DNA fragmentation comparison

Target conditions

infertilitysubfertility

Care settings

doctor’s officeclinichome (at-home kits)

Partnerships

Inherent Biosciences, Inc. (path is a brand)

Investors

Cadron Capital

News

Path Fertility Says “Normal” Sperm Tests Are Failing Couples — And a New Peer-Reviewed Study Backs Them Up - TechBuzz News · 2026-04-06T16:56:40.000Z
Path Fertility Releases its Company Facts Sheet | Newswire · 2026-03-10T14:05:00.000Z
Path Fertility Releases its SpermQT Facts Sheet | Newswire · 2026-03-17T12:35:00.000Z
Male Fertility Research Advancing Reproductive Medicine · 2025-02-18T19:19:12.000Z
Sapyen and Path Fertility Debut World’s First Home-to-Lab DNA Methylation Test in Global Partnership — Inherent Biosciences · 2025-09-23T21:08:00.000Z
A New Peer-Reviewed Report Highlights the Reality Facing Some Couples and the Information Your Infertility Doctor May Not Be Telling You · 2026-03-17T08:25:00.000Z

Browse similar startups

Related startups

Skyline Pharmacy — Mount Pleasant, UT
SoundPass Medical — Salt Lake City, UT
Tuva Health — Salt Lake City, UT
Verzi — Salt Lake City, UT
Vibrix Pharmacy — Lindon, UT
White Smiles Family Dentistry — Orem, UT
Pathfinder by Senior AI — Saint Louis, WA
Pathfinder Oncology — Chapel Hill, NC
PathoGene, Inc. — Monrovia, CA
PATHOMIQ, Inc. — Cupertino, CA
PATIENT CARE COORDINATION, INC. — Philadelphia, PA
Payson Healthcare Management, Inc. — Payson, AZ

Profile updated Jul 29, 2026. Sources: pathfertility.com